{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:41:55Z","timestamp":1793040115682,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jid.2026.01.047","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:12:38Z","timestamp":1776467558000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of biosimilars in enhancing global access to psoriasis treatment"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5318-9005","authenticated-orcid":false,"given":"Yasmina","family":"Behlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-056X","authenticated-orcid":false,"given":"Sean P.","family":"Gavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-7776","authenticated-orcid":false,"given":"Thomas","family":"Graier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8956-9807","authenticated-orcid":false,"given":"Bryan Edgar","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3933-0563","authenticated-orcid":false,"given":"Juan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9133-2008","authenticated-orcid":false,"given":"Rachel H.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-8332","authenticated-orcid":false,"given":"Alison K.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2958-915X","authenticated-orcid":false,"given":"Darren M.","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-1115","authenticated-orcid":false,"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-0457","authenticated-orcid":false,"given":"Claudia","family":"De La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4629-1486","authenticated-orcid":false,"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5891-5607","authenticated-orcid":false,"given":"Peter","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-3675","authenticated-orcid":false,"given":"Su","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-4427","authenticated-orcid":false,"given":"Christopher E.M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Peter C.M.","family":"Van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.01.047_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/d41573-024-00018-2","article-title":"The pipeline and market for psoriasis drugs","volume":"23","author":"Al-Horani","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2026.01.047_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40261-021-01089-4","article-title":"Health economic assessment of optimal biological treatment for moderate-to-severe psoriasis","volume":"41","author":"Barker","year":"2021","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jid.2026.01.047_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/862851","article-title":"Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle","volume":"2014","author":"Chi","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jid.2026.01.047_bib4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jaad.2019.12.033","article-title":"Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea","volume":"82","author":"Cho","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.01.047_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.mcpdig.2024.05.008","article-title":"Skin and digital-the 2024 narrative","volume":"2","author":"du Crest","year":"2024","journal-title":"Mayo Clin Proc Digit Health"},{"key":"10.1016\/j.jid.2026.01.047_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1476213","article-title":"Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China","volume":"12","author":"Du","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.jid.2026.01.047_bib7","article-title":"Psoriasis and health economic impact in a developing country like Nepal","volume":"191","author":"Dutta","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2026.01.047_bib8","article-title":"Global disparities in access to dermatological care: the skin health observatory","author":"Freeman","year":"2026","journal-title":"medRxiv"},{"key":"10.1016\/j.jid.2026.01.047_bib25","doi-asserted-by":"crossref","first-page":"E1055","DOI":"10.9778\/cmajo.20210091","article-title":"Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis","volume":"9","author":"Gomes","year":"2021","journal-title":"CMAJ Open"},{"key":"10.1016\/j.jid.2026.01.047_bib9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.329.7475.1169","article-title":"The concept of essential medicines: lessons for rich countries","volume":"329","author":"Hogerzeil","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2026.01.047_bib10","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2026.01.047_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2026.01.047_bib12","article-title":"The expiry of Humira\u00ae market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures","volume":"11","author":"Moorkens","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2026.01.047_bib13","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2214-109X(22)00460-0","article-title":"Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities","volume":"11","author":"Morin","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jid.2026.01.047_bib14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/03007995.2023.2214046","article-title":"Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany","volume":"39","author":"Nyholm","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jid.2026.01.047_bib15","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2026.01.047_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/14712598.2019.1636963","article-title":"Biosimilars for the treatment of psoriasis","volume":"19","author":"Puig","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jid.2026.01.047_bib17","first-page":"857","article-title":"The economic impact of ustekinumab in the treatment of psoriasis: a targeted literature review","author":"Shastri","year":"2024","journal-title":"Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2026.01.047_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/jdv.20367","article-title":"Belgian recommendations for managing psoriasis in a changing treatment landscape","volume":"39","author":"Speeckaert","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2026.01.047_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.12788\/j.sder.2018.040","article-title":"Ustekinumab for the treatment of psoriasis: an evidence update","volume":"37","author":"YIU","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jid.2026.01.047_bib23","doi-asserted-by":"crossref","DOI":"10.2196\/46295","article-title":"An mHealth app (eSkinHealth) for detecting and managing skin diseases in resource-limited settings: mixed methods pilot study","volume":"6","author":"Yotsu","year":"2023","journal-title":"JMIR Dermatol"},{"key":"10.1016\/j.jid.2026.01.047_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1186\/s12913-021-06866-7","article-title":"A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study","volume":"21","author":"Zagni","year":"2021","journal-title":"BMC Health Serv Res"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26010444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26010444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:20:32Z","timestamp":1780428032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X26010444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":22,"alternative-id":["S0022202X26010444"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.01.047","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of biosimilars in enhancing global access to psoriasis treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.01.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}